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and respiratory disease, and those with increased severity 
of illness.
Conclusion Prospective randomised trials are needed to 
clarify the significance of new-onset atrial fibrillation in 
sepsis, optimal treatment strategies for these patients, and 
the benefit of systemic anticoagulation. Physicians should 
be aware that new-onset atrial fibrillation in sepsis is not 
merely an observed temporary arrhythmia but a marker of 
poor prognosis and should be managed accordingly.
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Introduction
Sepsis represents a significant proportion of morbidity and 
mortality in the intensive care unit (ICU). Despite advance-
ments in therapy, mortality rates far exceed those of other 
medical conditions such as myocardial infarction and 
stroke. The development of new-onset atrial fibrillation is 
an indicator of poor prognosis in patients with critical ill-
ness. Atrial fibrillation occurs in up to 40 % of patients post 
coronary artery bypass graft implantation and up to 50 % 
post cardiac valve surgery [1, 2]. Prospective registries have 
demonstrated that postoperative atrial fibrillation is asso-
ciated with a threefold increase in postoperative compli-
cations such as myocardial infarction, heart failure, acute 
respiratory failure, and stroke.
Mechanism of new-onset atrial fibrillation in sepsis
The proposed mechanism for atrial fibrillation in sepsis 
involves the production of an anatomical and electrophysi-
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Background The development of new-onset atrial fibrilla-
tion in sepsis has been associated with adverse outcomes.
Methods A systematic literature search was conducted to 
retrieve articles that investigated the association of new-on-
set atrial fibrillation in patients diagnosed with sepsis. The 
primary outcome of interest was the pooled risk ratio (RR) 
of in-hospital mortality in patients with new-onset atrial fi-
brillation and sepsis.
Results Six studies included 3100 patients with new-onset 
atrial fibrillation in sepsis and 36,900 patients without new-
onset atrial fibrillation in sepsis. The pooled RR for in-hos-
pital mortality was 1.45 (95 % CI 1.32–1.60, p < 0.00001, 
I2 = 24 %). New-onset atrial fibrillation was also associated 
with increased ICU mortality, ICU and in-hospital length of 
stay and stroke. New-onset atrial fibrillation occurred more 
in the elderly, those with a prior history of cardiovascular 
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ological substrate as a consequence of a hyper-inflamma-
tory state [3−5]. Multiple imaging modalities demonstrate 
that patients with sepsis experience biventricular dilatation 
with both systolic and diastolic dysfunction. These changes 
are unrelated to coronary perfusion, and it is suggested that 
circulating cytokines and local production of cardio-depres-
sant factors are the underlying cause of this septic cardio-
myopathy [6−8]. Using an in-vitro myocardial assay, the 
effects of inflammatory cytokines derived from the serum 
of humans with septic shock were examined to assess its 
effects on myocardial contractile function. Independently 
and synergistically, tumour necrosis factor-alpha and inter-
leukin-1b showed a concentration-dependent depression in 
myocardial contractility; removal of both cytokines resulted 
in the elimination of serum myocardial depressant activity.
In the setting of this hyper-inflammatory state, the com-
bination of depressed myocardial function and large vol-
ume fluid resuscitation may result in an acute increase in 
left ventricular end-diastolic pressure and subsequent left 
atrial stretch, in turn providing an anatomical substrate upon 
which atrial fibrillation can occur. Furthermore, an indepen-
dent process of ventricular remodelling due to sepsis may 
decrease ventricular chamber compliance and may further 
alter left atrial and pulmonary venous haemodynamics. Sup-
port for this theory stems from population-based studies that 
confirm the importance of an anatomical substrate in the 
generation of atrial tachyarrhythmia [9].
In addition, there is evidence to suggest that systemic 
inflammation in sepsis induces an electrophysiological sub-
strate for atrial fibrillation. Aoki et al. investigated the role 
of ion channels in sepsis-induced atrial tachyarrhythmia. 
Sepsis was induced in guinea pigs through inoculation of 
lipopolysaccharide (LPS), an endotoxin from the cell wall 
of gram-negative organisms and known potent inducer of 
the systemic inflammatory cascade [10]. Post inoculation, 
atrial cells isolated from LPS-treated animals demonstrated 
significantly shortened action potential duration. These 
changes were associated with reduced L-type calcium cur-
rent and an increased delayed rectifier potassium current. 
Inducible nitric oxide synthase was found to be upregu-
lated, and atrial nitric oxide production was increased. The 
changes in action potential duration were reversed when 
LPS was co-administered with inhibitors of nitric oxide 
synthase. A shortened action potential duration in the set-
ting of sepsis may reflect an inflammation-induced nitration 
of ion channels which may contribute to the development of 
sepsis-induced atrial fibrillation. Future studies are needed 
to explore these proposed mechanisms.
Recent studies have investigated the association of new-
onset atrial fibrillation in patients with sepsis. New-onset 
atrial fibrillation has been associated with longer stay in 
hospital, and overall increased mortality. We provide a 
systematic review and meta-analysis of studies describing 
increased morbidity and mortality in patients with new-
onset atrial fibrillation and sepsis.
Methods
Study selection
A systematic search was conducted to retrieve articles that 
investigated the association of new-onset atrial fibrillation 
in patients diagnosed with sepsis. We identified potential 
English-language sources from the PubMed, Medline, and 
EMBASE databases from the year 1950 to December 2013. 
Keywords used were “atrial fibrillation” and (“sepsis” or 
“septic shock”). In addition, reference lists of any studies 
meeting inclusion criteria were reviewed manually to iden-
tify additional relevant publications.
Inclusion criteria
Studies were included that met the following criteria: (i) 
observational studies that evaluated patients with new-
onset atrial fibrillation with a diagnosis of sepsis or septic 
shock; (ii) patients who were admitted to a medical or sur-
gical intensive care unit; (iii) studies that include a control 
group of patients with a diagnosis of sepsis without new-
onset atrial fibrillation; (iv) studies that are published as a 
full article in the English language. Eligibility assessment 
and data extraction were carried out independently by two 
investigators (SG and DL) with discrepancies resolved by 
consensus in consultation with the senior author.
Outcomes of interest
The primary outcome of our meta-analysis was the pooled 
relative risk ratio (RR) of in-hospital mortality with a diag-
nosis of new-onset atrial fibrillation in sepsis. Meta-analysis 
was conducted by combining the risk ratios of individual 
studies into a pooled RR using a random-effects model. 
Relative RRs are reported with 95 % confidence intervals 
(CIs). We tested for heterogeneity using the chi-squared test 
and the I2 test. The I2 test describes the percentage of vari-
ability in effect estimates that is due to heterogeneity rather 
than chance. A value of 25 % suggests low variability, 50 % 
suggests moderate variability, and 75 % suggests high vari-
ability between studies [11]. Sensitivity analysis was con-
ducted for outcomes reported, funnel plots were constructed 
to assess for publication bias. Analyses was performed with 
RevMan 5.1 (Review Manager (RevMan) [Computer pro-
gram]. Version 5.1. Copenhagen: The Nordic Cochrane 




sepsis. Arora et al. performed a single-centre, prospective 
observational study of patients admitted to a medical-sur-
gical ICU [17]. Admission for sepsis was an independent 
risk factor for the development of new-onset atrial fibrilla-
tion (OR 4.87, p = 0.02) and patients in the new-onset atrial 
fibrillation group had higher in-hospital mortality (RR 2.7, 
p < 0.05). This study was excluded, as the authors could 
not provide specific outcomes for patients diagnosed with 
sepsis and new-onset atrial fibrillation. Kindem et al. retro-
spectively evaluated patients admitted with bacteraemia, and 
found that new-onset atrial fibrillation was associated with 
increased 14-day mortality. This study was excluded as only 
16 % of patients with new-onset atrial fibrillation met the 
systemic inflammatory response syndrome (SIRS) criteria, 
therefore not meeting the criteria for sepsis [18].
Salman et al. [19] assessed outcomes in patients with 
new-onset atrial fibrillation admitted to a surgical ICU. The 
authors of this study were contacted and provided the infor-
mation specifically for patients with a diagnosis of sepsis 
and the development of new-onset atrial fibrillation.
Overall eight studies were eligible for inclusion in the 
systematic review [19−26]. Table 1 summarises character-
istics for each individual study, Table 2 summarises patient 
characteristics, and Table 3 summarises study outcomes. We 
assessed the quality of included studies using the Newcas-
tle-Ottawa quality assessment scales. Overall, the quality of 
studies was quite high. Two studies scored nine points [20, 
23], one study scored eight points [19], one study scored 
seven points [21], three studies scored six points [24−26], 
and one study scored five points [22].
Meta-analysis of in-hospital mortality
Six studies met inclusion criteria for assessing in-hospital 
mortality in new-onset atrial fibrillation in patients with sep-
sis. Fig. 2 summarises the results of studies of in-hospital 
mortality in new-onset atrial fibrillation and sepsis. A total 
of 3100 patients with new-onset atrial fibrillation in sep-
sis were included, and 36,900 patients without new-onset 
atrial fibrillation in sepsis. A total of 1759 (57 %) patients 
with new-onset atrial fibrillation and sepsis experienced in-
hospital mortality, compared with 13,967 (38 %) without 
new-onset atrial fibrillation and sepsis. The pooled RR for 
in-hospital mortality in patients with new-onset atrial fibril-
lation was 1.45 (95 % CI 1.32–1.60, p < 0.00001, I2 = 24 %), 
demonstrating a significantly increased in-hospital mortal-
ity. Sensitivity analysis showed the results remained after 
removal of each study.
Morbidity and mortality
Eight studies met the inclusion criteria: five retrospective 
studies and three prospective studies. Walkey et al. per-
Study quality and data extraction
Quality assessment was carried out independently by two 
investigators (SG and DL) using the Newcastle-Ottawa 
quality assessment scale. Our assessment included studies 
based on three aspects: the selection of the study groups 
(0–4 points), the comparability of the groups (0–2 points), 
and the ascertainment of either the exposure or outcome of 
interest (0–3 points), with a maximum total score of 9. A 
score ≥ 5 indicated adequate quality for inclusion in the sys-
tematic review. Discrepancies in interpretation of data and 




Our search strategy yielded 270 studies, of which 255 were 
excluded on review of the title and abstract (Fig. 1). A further 
seven studies were excluded after careful review of the full 
text. Four narrative review articles were excluded as no new 
patient data were offered [12−15]. Seguin et al. performed a 
prospective observational study of trauma patients who were 
admitted to a surgical ICU [16]. New-onset atrial fibrillation 
was associated with a diagnosis of sepsis, and demonstrated 
increased ICU and hospital length of stay (p < 0.001). This 
study was excluded, as it could not provide specific outcomes 
for patients diagnosed with new-onset atrial fibrillation and 





Table 1 Study characteristics
Author (year) Study design Inclusion Exclusion Quality of studya
Walkey et al. [25] Retrospective California State Independent database claims, 
adults hospitalised with severe sepsis
n/a 6
Wells et al. [26] Retrospective Admitted to the medical ICU with sepsis Recent myocardial injury, 
malignancy
6
Kumar et al. [22] Retrospective Nationwide Inpatient Sample 2007 database, 
adults diagnosed with severe sepsis or septic 
shock
n/a 5
Meierhenrich et al. [23] Prospective Admitted to general surgical ICU, diagnosed 
with septic shock
If underwent cardiac surgery, 
previous history of known AF
9
Goodman et al. [12] Prospective Admitted to general surgical ICU, diagnosed 
with sepsis
Recent thoracic surgery, sus-
tained thoracic trauma
7
Salman et al. [19] Retrospective Admitted to a medical-surgical ICU diagnosed 
with sepsis, severe sepsis, septic shock
Previous AF 8
Christian et al. [20] Retrospective Admitted to a medical-surgical ICU diagnosed 
with sepsis
If underwent cardiothoracic 
injury, acute MI, acute pulmo-
nary embolism
9
Seguin et al. [24] Prospective Admitted to a surgical ICU AF on admission, permanent 
pacemaker
6
aNewcastle-Ottawa assessment scale. n/a not applicable, AF atrial fibrillation, ICU intensive care unit, MI myocardial infarction
Table 2 Patients characteristics
Author (year) Mean age (years), female Comorbidities
New-onset AF Control New-onset AF Control
Walkey et al. [25] 74, 44 % 66, 49 % Hypertension: 46 % Hypertension: 48 %
Diabetes mellitus: 28 % Diabetes mellitus: 34 %
CAD: 6 % CAD: 5 %
Stroke: 4 % Stroke: 2 %
CHF: 11 % CHF: 6 %
COPD: 7 % COPD: 5 %
Wells et al. [26] 72, 41 % 62, 45 % CAD: 40 % CAD: 19 %
COPD: 39 % COPD: 29 %
Diabetes Mellitus: 41 % Diabetes Mellitus: 33 %
Kumar et al. [22] n/a n/a n/a n/a
Meierhenrich et al. [23] 66, 22 % 56, 44 % Hypertension: 74 % Hypertension: 41 %
CAD: 22 % CAD: 7 %
CHF: 4 % CHF: 0 %
COPD: 17 % COPD: 4 %
Goodman et al. [12] 69, 50 % 53, 42 % Hypertension: 35 % Hypertension: 14 %
Diabetes mellitus: 37 % Diabetes mellitus: 7 %
CAD: 31 % CAD: 35 %
CHF: 4 % CHF: 15 %
COPD: 7 % COPD: 23 %
Salman et al. [19] 67, 28 % 56, 50 % Hypertension: 44 % Hypertension: 38 %
Diabetes mellitus: 16 % Diabetes mellitus: 27 %
CAD: 8 % CAD: 4 %
Stroke: 8 % Stroke: 4 %
COPD: 4 % COPD: 2 %
Christian et al. [20] 66 62.2 n/a n/a
Seguin et al. [24] 57, 13 % 41, 24 % Hypertension: 6 % Hypertension: 10 %
CAD: 6 % CAD: 3 %
Chronic lung disease: 6 % Chronic lung disease: 4 %




57 %, p < 0.0001). Kumar et al. published results of their 
retrospective, observational study and found that new-onset 
atrial fibrillation compared with sinus rhythm was associ-
ated with increased mortality in patients with severe sep-
sis (OR 1.19, 95 % CI 1.14–1.24, p < 0.05) and septic shock 
(OR 1.12, 95 % CI 1.07–1.18, p < 0.05) [22]. Meierhenrich 
performed a single-centre, prospective observational study 
of patients admitted to a general surgical ICU with a diagno-
sis of septic shock excluding those who underwent cardiac 
surgery [23]. Patients with new-onset atrial fibrillation com-
pared with sinus rhythm were older (mean age of 66 years 
compared with a mean age of 56 years, p < 0.01) and fre-
quently had a history of hypertension (p = 0.02). There was 
formed a retrospective study of hospitalised patients with 
severe sepsis. Patients with new-onset atrial fibrillation in 
sepsis compared with sepsis with sinus rhythm were older 
(mean age of 74 years compared with 66 years) and had 
increased risk of in-hospital mortality with a combined mul-
tivariate adjusted RR 1.07 (95 % CI 1.04–1.11, p < 0.001) 
[25]. A single-centre, retrospective study by Wells found 
patients with new-onset atrial fibrillation in sepsis compared 
with sinus rhythm were older (mean age 72 years compared 
with 62 years, p < 0.0001), and were more likely to have cor-
onary artery disease (p < 0.0001) [26]. In-hospital mortality 
was significantly increased in patients with new-onset atrial 
fibrillation and sepsis compared with sepsis alone (72 % vs. 
Table 3 Study outcomes
Author (year) Significant results
Walkey et al. [25] New-onset AF in sepsis vs. sepsis alone In-hospital ischaemic stroke OR 2.70 (2.05–3.57, p < 0.001)
In-hospital mortality RR 1.07 (1.04–1.11, p < 0.001)
Wells et al. [26] New-onset AF in sepsis vs. sepsis alone In-hospital mortality 72 % vs 57 %, p < 0.0001
Kumar et al. [22] New-onset AF Frequency in severe sepsis OR 1.1 (1.13–1.19, p < 0.05)
Frequency in septic shock OR 1.33 (1.29–1.37, p < 0.05)
In-hospital mortality of new-onset AF and 
severe sepsis or septic shock vs. severe 
sepsis or septic shock alone
Severe sepsis OR 1.19 (1.14–1.24, p < 0.05)
Septic shock OR 1.12 (1.07–1.18, p < 0.05)
Meierhenrich et al. [23] New-onset AF in severe sepsis vs. sepsis 
alone
ICU mortality 39 % vs. 22 %, p = 0.14
28-day mortality 39 % vs. 22 %, p = 0.22
60-day mortality 48 % vs. 26 %, p = 0.14
Median ICU LOS (days) 30 vs. 17, p = 0.017
Goodman et al. [12] New-onset SVA and sepsis vs. sepsis alone In-hospital mortality OR 1.99 (1.09–3.64, p = 0.026)
Salman et al. [19] Paroxysmal AF and sepsis vs. sepsis alone ICU mortality 48 % vs. 27 %, p = 0.0614
In-hospital mortality 64 % vs. 36 %, p = 0.018
28-day mortality 72 % vs. 38 %, p = 0.041
Median ICU LOS (days) OR 3.284 (1.126–9.574, p = 0.0294)
8 vs. 3, p = 0.0087
Christian et al. [20] New-onset AF and sepsis vs. sepsis alone ICU mortality 68.8 % vs. 39.8 %, p = 0.034
Median ICU LOS (days) 27.8 vs. 7.6, p = 0.0001
Hospital LOS (days) 63.4 vs. 29.4, p = 0.047
Mechanical ventilation (days) 23.58 vs. 8.35, p = 0.006
Seguin et al. [24] New-onset AF and sepsis vs. sepsis alone In-hospital mortality 25 % vs. 11 %
AF  atrial fibrillation,  ICU  intensive care unit, LOS   length of stay, OR  odds ratio, RR   relative risk, SVA  supraventricular arrhythmia





sis showed patients with new-onset atrial fibrillation had 
a greater risk of stroke than those with pre-existing atrial 
fibrillation (OR 3.63, 95 % CI 2.51–5.25, p < 0.001). New-
onset atrial fibrillation in sepsis compared with sepsis with 
sinus rhythm demonstrated a trend towards increased risk of 
re-hospitalisation with incident ischaemic stroke (multivari-
able analysis HR 1.51, 95 % CI 0.98–2.33, p = 0.06).
Rhythm versus rate control
Meierhenrich et al. treated 49 of 50 patients with new-onset 
atrial fibrillation in sepsis [23]. Electrical cardioversion was 
performed with adjuvant pharmacological agents in 17 of 
49 patients. Amiodarone was used most frequently in 36 
patients, and beta-blockers in 25 patients indicating that 
the majority of patients received a combination of antiar-
rhythmic drugs. In 42 of the 49 patients with new-onset 
atrial fibrillation, sinus rhythm was successfully reconsti-
tuted. Failure to restore sinus rhythm was associated with 
increased ICU mortality, as 5 of the 7 patients who could 
not maintain sinus rhythm died compared with 9 of the 42 
patients who were successfully converted to sinus rhythm 
(p = 0.015).
Discussion
The studies presented demonstrate that new-onset atrial 
fibrillation is associated with increased ICU mortality, in-
hospital mortality, ICU length of stay, in-hospital length of 
stay, stroke, and adverse outcomes post discharge. New-
onset atrial fibrillation occurred more in elderly patients, 
those with a prior history of cardiovascular and respiratory 
disease, and those with increased severity of illness. The 
study by Meierhenrich et al. suggests that in the ICU set-
ting, rhythm control may be desirable given the increased 
mortality rate among those unable to achieve sinus rhythm.
Our study is the first systematic review in the literature to 
describe the association of new-onset atrial fibrillation with 
poor outcomes in patients with sepsis. This includes clini-
cal characteristics and risk factors for adverse outcomes, 
as well as insight into the development of in-hospital and 
long-term stroke, and possible benefit of rhythm control. 
The strength of this study is the pooled analysis of 3100 
patients that demonstrates increased in-hospital mortality in 
this patient population.
There are several limitations to the interpretation of our 
systematic review and meta-analysis. The retrospective obser-
vational nature of these studies limits our ability to assess for 
covariates of increased mortality. Due to the design of these 
studies, it is unclear what the primary diagnosis or preced-
ing illness was before being labelled as ‘sepsis’, the source of 
the infection or responsible organisms, specific details around 
no difference between doses and frequency of vasopressors, 
SAPS II score, and serum electrolytes between both groups. 
Mortality was increased in patients with new-onset atrial 
fibrillation and septic shock compared with sepsis with 
sinus rhythm, however did not reach statistical significance. 
Salman et al. performed a single-centre, retrospective cohort 
study of patients admitted to a medical-surgical ICU with a 
diagnosis of sepsis [19]. Patients with new-onset atrial fibril-
lation had higher APACHE III scores (p = 0.0091) and lower 
mean ejection fractions (48.9 % vs. 59.1 %, p = 0.0322). The 
atrial fibrillation group demonstrated increased in-hospital 
mortality (64 % vs. 36 %, p = 0.018), 28-day mortality (72 % 
vs. 38 %, p = 0.041), and median length of ICU stay (8 days 
vs. 3 days, p = 0.0087). Multiple logistic regression analy-
sis demonstrated that new atrial fibrillation was associated 
with increased risk of mortality at 28 days (OR 3.284, 95 % 
CI 1.126–9.574, p = 0.0294). Christian et al. performed a 
single-centre, retrospective observational study of patients 
admitted to a medical-surgical ICU with a diagnosis of sep-
sis [20]. Patients with sepsis and new-onset atrial fibrillation 
compared with sinus rhythm had increased ICU mortality 
(68.8 % vs. 39.8 % p = 0.034). Patients with new-onset atrial 
fibrillation and sepsis had increased ICU length of stay (27.8 
days vs. 7.6 days, p = 0.0001), increased hospital length of 
stay (63.4 days vs. 29.4 days, p = 0.047), and increased need 
for mechanical ventilation (23.58 ventilation days vs. 8.35 
ventilation days. p = 0.006). Goodman et al. performed a 
prospective, single-centre study of patients admitted to a 
surgical ICU excluding those who underwent recent tho-
racic surgery or sustained thoracic trauma [21]. New-onset 
supraventricular arrhythmia (SVA) in patients with sepsis 
was associated with an increased risk of in-hospital mor-
tality (OR 1.99, 95 % CI 1.09–3.64, p = 0.026) and signifi-
cantly longer hospital stays (p < 0.01) independent of age. 
After four years of follow-up, overall mortality was higher 
in patients with new-onset SVA; however, most of these 
deaths occurred in the first year post hospitalisation. Seguin 
et al. performed a single-centre, prospective observational 
study of patients admitted to a surgical ICU excluding those 
with prior documented atrial fibrillation or a permanent 
pacemaker [24]. New-onset atrial fibrillation was associ-
ated with increased age (p = 0.001), history of cardiovascu-
lar disease (p = 0.02), and use of calcium channel blockers 
(p = 0.002). Of patients with new-onset atrial fibrillation and 
sepsis, 25 % died in hospital compared with 11 % of patients 
with sepsis and sinus rhythm.
Stroke
In the study by Walkey et al. [25], 75 of 2896 (2.6 %) 
patients with new-onset atrial fibrillation and sepsis suffered 
from in-hospital ischaemic stroke (multivariable adjusted 
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mortality, as well as the management strategy. In our pooled 
analysis of in-hospital mortality, Walkey et al. included 39,096 
subjects which comprised 94 % of the subjects; however, the 
results remained after sensitivity analysis. This confirms that 
our results are representative to the population of the subjects 
included. In regards to an association of increased stroke, 
there are several limitations to the interpretation of this analy-
sis due to data extraction based upon billing codes, as well as 
the lack of insight regarding anticoagulation practices during 
the admission and upon discharge of the patients.
Prospective randomised trials are needed to help clarify 
the significance of the development of atrial fibrillation in 
sepsis, and to assess the optimal treatment strategies for 
patients with atrial fibrillation in the ICU. Current guidelines 
do not offer recommendations regarding anticoagulation 
for stroke risk reduction in patients with new-onset atrial 
fibrillation in sepsis. Future datasets need to be analysed 
to fully assess the risk of stroke in this patient population 
and to assess the benefit of systemic anticoagulation along-
side the risk of adverse bleeding. New-onset atrial fibrilla-
tion in septic patients is likely a marker of poor prognosis 
and increased mortality. Measures to improve outcomes 
such as maintaining adequate perfusion pressure with sinus 
rhythm and reducing the risk of stroke with anticoagulation 
should be considered in the management of patients with 
new-onset atrial fibrillation in the ICU. Physicians should 
be aware that new-onset atrial fibrillation in sepsis is not 
merely an observed temporary arrhythmia but is a marker of 
poor prognosis and should be managed accordingly.
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